Search Results for: medical marijuana

What Is the Right Process to Get Your Medical Marijuana Card Online?

Getting a medical marijuana card is not difficult as long as you have the medical conditions that qualify you for it. All you need to do is find a doctor who will perform the necessary evaluation and provide you with a recommendation. Today, you don’t even need to visit the doctor for an assessment. You can use the online facilities that allow for video call evaluation.

After the doctor has determined that you qualify for the card, you can send your application to the state along with the physician’s recommendation. The state will provide you with your medical marijuana card once you are verified.

If you are wondering how to go about this entire process of getting medical marijuana card online, here is a clear step-by-step guide that will enlighten you:

Book an appointment

Since you are going through the online process of acquiring your card, you will not need to worry about geographical or physical barriers to contact a doctor. Set up an online appointment and communicate with the doctor about all your medical issues and why you require a medical marijuana card. You can do this on your cell phone, tablet or computer.

Get a Doctor’s Recommendation

A recommendation is a document provided by a doctor who has evaluated your medical condition and determines that cannabis will benefit your health. You need to have one of the qualifying medical conditions expected from your state to be eligible for a medical marijuana card. The evaluation can take a maximum of 30 minutes, depending on your medical complications.

These medical ailments can vary from state to state, but the following are the most common ones:

  • Chronic Pain
  • Anxiety and/or depression
  • PTSD
  • Cancer
  • Seizures
  • Glaucoma
  • HIV/AIDS
  • Hepatitis C
  • Crohn’s disease
  • Terminal Illness
  • Ulcerative colitis
  • Multiple sclerosis
  • Parkinson’s disease
  • Alzheimer’s disease
  • Chronic muscle spasms

 

Every state program is different. A few, such as California, Maine and Louisiana, don’t require any further applications. But most do involve some paperwork.

When you are sending over your application for the medical marijuana card, you need to fill the given form with the required details. Most states require the following details to approve your request for a medical marijuana card:

  • Name and mailing address
  • Residence address
  • Date of birth
  • Phone number
  • Email ID
  • Doctor name
  • Patient Signature

You will also have to submit the following documents along with the application form and the doctor’s recommendation:

  • Address proof (digital, color copy)

You can choose any state-approved proof of residence, such as Driver’s License, Government-issued ID, Voter’s ID, In-State Property Deed, latest Rental Agreement, or Utility Bills (previous month)

  • Identity Proof (digital, color copy)

You can choose from Driver’s License, Government-issued ID, U.S. Passport/other U.S. ID, or government-approved Tribal ID card.

  • Other documents

You will also need a full-face digital, color photograph, the doctor’s recommendation form.

When Will You Receive the Medical Marijuana Card?

After you submit your application with all the required documents, you will have to wait for the state’s approval of your request for a medical marijuana card. If everything is in order and the state finds you eligible, you will receive your card in due course. Approvals range from a few days to a month, depending on the state.

In case you haven’t filled the application correctly or completely, you will be notified through email. You can refill the application and submit it to the agency. You will have to go through the same waiting process till you receive your card. If, for any reason, your application is denied, then you will be notified as to why you did not qualify.

What is the Card Validity Period?

Most states issue 1 year cards but some offer longer certificates such as 2 years in Oklahoma or 3 years in Illinois. Florida, alternatively, only issues cards for 30 weeks! Check with your physician how long your certificate will be valid for.

How Do I Buy My Medications?

You can buy your medications from any state-approved dispensary. The state does not require a doctor’s prescription for you to buy medical cannabis products. Technically, a doctor can only recommend a cannabis product after evaluating your health. You can choose the products you want to consume and in any form or potency recommended to you.

Overall, this is a very simple process, especially since the state accepts individuals who apply for their medical marijuana card online. If you are looking to benefit from the use of medical marijuana, then you should consult a doctor and get your recommendation right away.

Medical Marijuana Program Celebrates Five-Year Anniversary, Continues Commitment to Patients in Pennsylvania

PENNSYLVANIA:  Governor Tom Wolf today commemorated the five-year anniversary of Act 16 of 2016, better known as the Pennsylvania Medical Marijuana Act, which established the medical marijuana program in the commonwealth.

Close to 553,000 patients and caregivers are registered for the program in order to obtain medical marijuana for one of 23 serious medical conditions. There are more than 327,400 active certifications as part of the program.

“On the five-year anniversary of the creation of Pennsylvania’s medical marijuana program, we continue to forge ahead in getting medicine to those with serious medical conditions,” Gov. Wolf said. “The work that the Department of Health does to ensure that products are available and that patients are able to receive medicine as seamlessly as possible, particularly during the pandemic, is exemplary.”

All of the 114 operational dispensaries are open and dispensing products to patients. Twenty-eight grower/processors are operational, with 23 shipping product to dispensaries. Many of these grower/processors have recently expanded their location, or are in the process of doing so to help ensure that they are able to provide more products to those with one of the 23 serious medical conditions eligible for use of medical marijuana products.

“In addition to the well-run medical marijuana program, the department is very proud of its unique and first-of-its-kind medical marijuana research program,” said Acting Sec. of Health Alison Beam. “It is clear that the Pennsylvania Medical Marijuana Program is among the most successful programs across the country.”

The clinical research program, guided by Act 43 of 2018, allows for eight clinical registrants who each must hold both a grower/processor and a dispensary permit. Clinical registrants must have a research contract with one of eight approved academic clinical research centers.

Active cardholders are continuing to visit dispensaries more than once a month to get treatment for a serious medical condition. More than 31.2 million products have been sold since the start of the program, and total sales within the program are close to $2.6 billion, which includes sales by the grower/processors to the dispensaries, and sales by the dispensaries to patients and caregivers. More than $1.5 billion in sales has been from the dispensaries to patients.

More than 2,100 physicians have registered for the program, more than 1,530 of whom have been approved as practitioners.

“From before I signed the Act, the state’s medical marijuana program’s success has been a tribute to the support received from patients and caregivers,” Gov. Wolf said. “The dedication from patients and caregivers in offering guidance and support is a testament to the value of this significant program.”

As a sign of the program’s continued commitment to get medical marijuana to patients, in March of 2020 the program temporarily suspended certain statutory and regulatory provisions in order to improve access to this form of medication during the COVID-19 emergency to:

  • Allow dispensary employees to provide medical marijuana to cardholders in their vehicles on the facility’s property;
  • Remove the current cap that limits the number of patients assigned to one caregiver, to allow for more caregivers to patients in need;
  • Eliminate background checks for caregiver applications, limited to renewal applications only, in order to expedite the caregiver renewal process;
  • Suspend in-person consultations and allow for remote consultations between approved practitioners and medical marijuana patients; and
  • Suspend limitation on medical marijuana dispensing to 30 days by requiring approved practitioners to notate on the patient’s certification to dispense a 90-day supply.
  • Suspend requirement for a medical professional – physician, pharmacist, physician assistant or certified registered nurse practitioner – to be on site at the dispensary during dispensing hours, which allows for medical professionals to work remotely.

The statutory and regulatory suspensions will remain in place for as long as the Proclamation of Disaster Emergency is in effect.

Ohio Medical Marijuana Control Program Mandatory Product Recall – 3/16/21

OHIO:  The Ohio Medical Marijuana Control Program (MMCP) is issuing a mandatory product recall on plant material sold to dispensaries by processor, GTI Ohio, LLC. This recall is being initiated by the MMCP because the product did not receive the full battery of required testing prior to being sold at dispensaries. The recalled products were not tested for heavy metals and mycotoxins. The MMCP is investigating this matter and will issue an executive summary at the conclusion of the investigation.

AFFECTED PRODUCTS:
Product Name:
  • “& Shine” Select Grind Lightly Ground Trim – Strain Name Koala Mints
  • “& Shine” Select Grind Lightly Ground Trim – Strain Name Blueberry Cheesecake
  • “& Shine” Select Grind Lightly Ground Trim – Strain Name Wedding Cake
Purchase Dates: February 15, 2021 – Present
Products Purchased from: RISE Dispensary (Cleveland), RISE Dispensary (Lakewood), RISE Dispensary (Lorain), and RISE Dispensary (Toledo)
Processor Name: GTI Ohio LLC
Product ID:
  • M00000144218: Tier 1 Vap-Hybrid-13.6-0-14.15
  • M00000145710: Tier 1 Vap-Hybrid-21.1-0-14.15
  • M00000145715: Tier 1 Vap-Hybrid-14.5-0-14.15
  • M00000146514: Tier 1 Vap-Hybrid-21.6-0-14.15
No reports of adverse reactions for this product have been reported to the MMCP at this time.
Patients who have purchased the recalled product should stop using it. All unused product should be returned to the dispensary where purchased. Returned products will not count toward a patient’s 90-day possession limit. For more information on returns, please contact the dispensary where the product was purchased.
Anyone who thinks that they may be experiencing serious or life-threatening issues should seek immediate medical attention. Patients are reminded that any adverse reactions should be reported to the MMCP toll-free helpline (1-833-464-6627).

Ohio Medical Marijuana Advisory Committee March 2021 Meeting Notice

Update from the Ohio Medical Marijuana Control Program

 

MEETING NOTICE MEDICAL MARIJUANA ADVISORY COMMITTEE

March 25, 2021

10:00 a.m.

OHIO: The Advisory Committee meeting will be held virtually via Microsoft Teams.  Instructions to access the Teams Meeting will be posted here the morning of March 25, and via email update.
To register for email updates please visit our website.
NOTE: The Advisory Committee will not be accepting testimony or public comments at this meeting. Public comment can be submitted at: www.medicalmarijuana.ohio.gov/contactus.

Maine Regulators Update Medical Marijuana Rules

MAINE:  The Office of Marijuana Policy today released preliminary draft rules meant to bring the state’s Medical Use of Marijuana Program regulations into congruence with state law. Administrative rulemaking is a standard process within government and, in this case, necessitated due to significant changes that have been made to state law since rules were last revised in February 2018, pre-dating the creation of OMP.

In addition to being thematically reorganized to better reflect the structure of Maine’s Medical Use of Marijuana Program, one of the most notable changes included in the draft is the introduction of a process by which medical marijuana establishments are regulated at the local level prior to state review, as is currently mandated by law. Additionally, the draft rules include provisions for inventory tracking to enhance accountability and transparency and delineate packaging and labeling requirements that prioritize patient protections.

“Along with being more user-friendly, these draft rules are meant to address changes to state law over the last two years. This draft framework will further ensure our regulatory priorities of safety, accountability, and transparency,” said OMP Director Erik Gundersen. “As relationships with local communities, industry, and other stakeholders are at the heart of all we do, we look forward to connecting with the public throughout the rule-making process.”

Current plans call for OMP to engage in both an informal and formal public comment period as it considers and develops revisions to the revamped medical rule. This approach is modeled after OMP’s development of the adult use program’s rules, an experience which allowed the Office to receive critical feedback and, ultimately, propose a better rule when beginning the formal rulemaking process defined by the Maine Administrative Procedures Act.

A copy of the preliminary draft rules is currently available for review on the OMP website: https://www.maine.gov/dafs/omp/medical-use/rules-statutes/rulemaking/draft-rules. Parties interested in providing feedback in response to the preliminary draft rules may do so through the following page: https://www.maine.gov/dafs/omp/medical-use/rules-statutes/rulemaking/feedback.

In line with the state’s standard rule-making process, the preliminary draft will transition into a proposed rule over the coming weeks, and OMP will begin the public hearing and public comment phase required by statute. A final draft of the proposed rule will be provided at least 20 days prior to the date of a scheduled public hearing. Following the public hearing, at least 10 days of written public comment will be allowed.

Once the public comment period concludes, OMP will review and consider all feedback received, make any appropriate revisions to the proposed rule, and complete final adoption.

House Approves Blumenauer’s Medical Marijuana Research Act

Legislation removes barriers to much-needed research on health benefits of marijuana.

DISTRICT OF COLUMBIA:Today (12/9/2020), the U.S. House of Representatives approved the Medical Marijuana Research Act, bipartisan legislation introduced by U.S. Reps. Earl Blumenauer (D-OR) and Andy Harris (R-MD) to address burdensome impediments to legitimate medical research.

Although 99 percent of Americans now live in a state with some form of legalized marijuana, current federal law greatly limits researchers’ ability to study the health benefits of cannabis. Current barriers include the overly burdensome registration process, redundant protocol reviews, lack of adequate research material, and unnecessarily onerous security requirements.

“The cannabis laws in this country are broken, especially those that deal with research. It’s illegal everywhere in America to drive under the influence of alcohol, cannabis, or any other substance. But we do not have a good test for impairment because we can’t study it … This is insane and we need to change it,” Blumenauer said today on the House floor. “At a time when there are four million registered medical cannabis patients, and many more likely self-medicate, when there are 91 percent of Americans supporting medical cannabis, it’s time to change the system. Our bill will do precisely that.”

While the United States leads the world in biomedical research, research on cannabis lags far behind. A 2017 National Academies of Sciences, Engineering, and Medicine report found that “research on the health effects of cannabis and cannabinoids has been limited in the United States, leaving patients, health care professionals, and policy makers without the evidence they need to make sound decisions regarding the use of cannabis and cannabinoids.”

The Medical Marijuana Research Act will address these limitations by:

  • Providing a pathway for researchers to study the cannabis products consumers are using from state-legal programs.
  • Streamlining the burdensome and often duplicative license process for researchers seeking to conduct marijuana research, while still maintaining all necessary safeguards against misuse and abuse.
  • Addressing the woefully inadequate, both in quantity and quality, supply of medical-grade marijuana available for use in such research.
  • Requiring a report by the secretary of the U.S. Department of Health and Human Services on the status and results of new research on marijuana benefits.

This was the second vote held by the U.S. House of Representatives in the past week on Blumenauer’s federal cannabis reform priorities, following the passage of the Marijuana Opportunity Reinvestment and Expungement (MORE) Act on Friday, December 4.

The full text of the Medical Marijuana Research Act can be found here.

NEW JERSEY: TerrAscend Issued Permit To Dispense Medical Marijuana In Phillipsburg As “The Apothecarium”

The Facility, doing business as “The Apothecarium,” is Now the 13th Dispensary Statewide, First in Warren County

NEW JERSEY: The New Jersey Department of Health today issued a permit allowing TerrAscend to begin dispensing medical cannabis in Phillipsburg.  TerrAscend is operating their dispensary under the name, “The Apothecarium.”  This is the 13th facility dispensing marijuana for medical use in New Jersey and the first to operate in Warren County.

The Phillipsburg location is set to open tomorrow, November 24th. TerrAscend is currently cultivating and processing in Boonton Township.

“Expanding access to our growing patient population continues to be a high priority especially during these unprecedented times,” said Health Commissioner Judith Persichilli. “The opening of this site will provide residents in the Northwestern New Jersey better access to products they need to treat their conditions.”

TerrAscend Corp. | CSE - Canadian Securities Exchange

The 12 other ATCs currently dispensing include Ascend Wellness of Montclair, The Botanist (Compassionate Care Foundation) of Egg Harbor and Atlantic City, Garden State Dispensary of Woodbridge, Eatontown and Union Township, Breakwater Alternative Treatment Center of Cranbury, Curaleaf NJ, Inc. in Bellmawr, Harmony Dispensary in Secaucus, Rise in Paterson, Zen Leaf Elizabeth and Columbia Care in Vineland.

Participation in the program continues to grow. There are currently over 97,500 patients, 3,600 caregivers and 1,250 physicians enrolled.

Patients and caregivers can visit the Division of Medicinal Marijuana’s website if they choose to change their preferred ATC. The change can also be made by calling the Customer Service Unit of the Division at 844-419-9712 and does not require changing ID cards.

Patients can refer to the FAQ section of the website for additional information. Active physicians enrolled in the program are listed by county and medical specialty.

New Jersey residents interested in registering for medicinal marijuana can click here.  Registration requires an authorization by a participating physician.

Ohio Medical Marijuana Advisory Committee November 2020 Virtual Meeting Link

 

OHIO: The Medical Marijuana Advisory Committee will hold a meeting virtually via Skype at 10:00 AM. Click here for a link to access the virtual meeting.

To join by phone, call 614-721-2972 and use access code 931714645.

 

Ohio Medical Marijuana Advisory Committee November 2020 Meeting Agenda

 

OHIO: The Medical Marijuana Advisory Committee will hold a meeting virtually via Skype on November 12, 2020.

AGENDA MEDICAL MARIJUANA ADVISORY COMMITTEE MEETING

November 12, 2020 10:00 a.m.

The Advisory Committee meeting will be held virtually via Skype.

Instructions to access the Skype Meeting will be posted here the morning of November 12, and via email update.

NOTE: The Advisory Committee will not be accepting testimony or public comments at this meeting.

10:00 a.m.

ROLL CALL AND MINUTES REVIEW

▪ Advisory Committee Members

10:05 a.m.

MEDICAL MARIJUANA CONTROL PROGRAM UPDATE

▪ Patient and Caregiver Update (Maerten-Moore)

▪ Dispensary Update (Maerten-Moore)

▪ Program Update (Maerten-Moore)

▪ Patient Survey Results (Maerten-Moore)

▪ Commerce Licensee Updates (McIlvaine)

▪ Program Sales and Product Data (McIlvaine)

▪ Commerce Initiatives (McIlvaine)

▪ Petitions for Qualifying Conditions (Pollock) o Current petition period and criteria o 2021 petition period dates

▪ Physicians with a CTR (Pollock)

▪ COVID-19 Update (Pollock)